Market News
Stay updated with the latest market trends, earnings, and economic indicators.
JBM Auto stock jumps 3% as subsidiary secures ₹750 crore investment from Motilal Oswal to scale e-bus deployment in India - Upstox
JBM Auto stock jumps 3% as subsidiary secures ₹750 crore investment from Motilal Oswal to scale e-bus deployment in IndiaUpstox
JBM Auto gains after subsidiary secures Rs 750-cr investment from Motilal Oswal Alternates
JBM Auto added 1.86% to Rs 705.20 after the company's subsidiary JBM ECOLIFE Mobility, has successfully secured a Rs 750 crore long term strategic investment from Motilal Oswal Alternates, the alternative investment arm of Motilal Oswal Group.
JBM Auto secures Rs 750 crore investment for e-bus deployment
JBM Auto's unit has secured a significant Rs 750 crore long-term investment from Motilal Oswal to deploy 2,000 e-buses and bolster India's sustainable public transit. This substantial capital infusion will accelerate the rollout of zero-emission fleets across key Indian cities, marking a major step in the nation's electric mobility transition.
JBM Ecolife raises Rs 900 crore from Motilal Oswal Fund for biz expansion
JBM Ecolife Mobility, JBM Auto's electric mobility arm, secured ₹900 crore from Motilal Oswal Private Credit via debt and equity. This funding will bolster its electric bus expansion, enabling participation in tenders and execution of contracts. The capital infusion is projected to scale the platform to nearly 5,000 buses from its current 2,000.
Tata Motors PV shares plunge 10% after weaker than expected JLR FY27 guidance
Tata Motors Passenger Vehicles shares dropped significantly. This followed Jaguar Land Rover's investor day where its financial outlook for fiscal year 2027 was revealed. Profitability guidance fell short of analyst expectations. JLR projects revenue growth and improved EBIT margins. North America remains a key focus for future growth. The company plans to invest in new segments and high-potential markets.
Motilal Oswal Financial Services among 5 F&O stocks with a sharp rise in futures open interest
Motilal Oswal Financial Services was among five NSE F&O stocks witnessing a sharp rise in futures open interest on June 15. The overall OI increase exceeded 7%, indicating fresh long or short build-up. Other stocks showing notable OI gains included Radico Khaitan, Bajaj Auto, Cochin Shipyard and Tata Power.
Shares to buy or sell: Chandan Taparia of Motilal Oswal recommends three stocks to buy today - 16 June 2026
Shares to buy or sell: Chandan Taparia has recommended three stocks to buy today, 16 June 2026 - Bharat Forge, BSE and The Phoenix Mills shares.
Mercedes-Benz India confident of sustaining growth on strong demand this year
The premium car maker also said that a price increase was on the cards to deal with the impact of sustained pressure on Indian Rupee, among others, a top company official said.
Why top fund managers think foreign investors could return to India
India's market outlook is improving as oil prices ease and geopolitical risks recede. Sunil Singhania, Founder of Abakkus Asset Manager, Prashant Khemka, Founder, Whiteoak Capital and Nilesh Shah, Managing Director at Kotak Mahindra AMC explain why foreign investor sentiment could improve, where earnings growth is strongest, and which sectors—from banks to renewables—offer the most compelling opportunities.
Analyst suggests buying Nestle India, Bharat Forge today: Check targets
Stocks to buy: Ruchit Jain of Motilal Oswal Financial Services has recommended buying the shares of Nestle India, and Bharat Forge today
Nifty 500 Q4 Review: HDFC Bank, Indian Oil, Tata Motors Among Top Winners, Losers; Key Sector Trend — Read Motilal Oswal's Report
Of the 23 key sectors, 14 posted double-digit profit growth in Q4 FY26.
PE investor BC Investments sells Rs 612 crore stake in Emcure Pharma; Kotak MF picks up stake
Private equity firm BC Investments IV sold a Rs 612 crore stake in Emcure Pharmaceuticals to Kotak Mahindra Mutual Fund at Rs 1,700 per share. Despite this divestment, analysts remain positive on Emcure's growth outlook across its core therapeutic segments.